| Autor: |
McCabe KW; Sterne, Kessler, Goldstein & Fox; P.L.L.C., Washington, DC, USA. kmccabe@skgf.com , Calvo PA |
| Jazyk: |
angličtina |
| Zdroj: |
MAbs [MAbs] 2009 Nov-Dec; Vol. 1 (6), pp. 600-3. Date of Electronic Publication: 2009 Nov 14. |
| DOI: |
10.4161/mabs.1.6.10204 |
| Abstrakt: |
Product life cycle management, which necessarily utilizes a multi-disciplinary approach, is an essential tool for companies that develop or market therapeutic monoclonal antibodies (mAbs). Too little attention to such a plan, or use of the wrong resources, could substantially curtail a product's life span. The most difficult part of the therapeutic antibody business is the development of high-quality, safe and effective products. Great care should thus be taken to ensure that products with these characteristics are positioned in a marketplace that is competition-free for as long as possible. In an era of mAbs with billion dollar markets, the loss of even a single day of sales could cost companies millions of dollars in lost revenue. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
